Viewing Study NCT03552692

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:36 PM
Ignite Modification Date: 2026-02-03 @ 3:16 PM
Study NCT ID: NCT03552692
Status: TERMINATED
Last Update Posted: 2023-12-12
First Post: 2018-05-10
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
Sponsor: Fondazione Italiana Linfomi - ETS
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None T-Cell Lymphoma Relapsed View
None T-Cell Lymphoma Refractory View
Keywords:

Keywords

Keyword Brief Keyword Text View
None BCL-2 positive View
None PTCL-NOS View
None angioimmunoblastic T-cell lymphoma (AITL) View
None T-follicular helper origin (TFH) View
None Venetoclax View
None single agent View